Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2007 1
2008 5
2009 8
2010 11
2011 8
2012 8
2013 16
2014 20
2015 35
2016 33
2017 39
2018 48
2019 45
2020 66
2021 96
2022 84
2023 95
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetic regulation of melanogenesis.
Zhou S, Zeng H, Huang J, Lei L, Tong X, Li S, Zhou Y, Guo H, Khan M, Luo L, Xiao R, Chen J, Zeng Q. Zhou S, et al. Among authors: li s. Ageing Res Rev. 2021 Aug;69:101349. doi: 10.1016/j.arr.2021.101349. Epub 2021 May 10. Ageing Res Rev. 2021. PMID: 33984527 Review.
Roles of inflammation factors in melanogenesis (Review).
Fu C, Chen J, Lu J, Yi L, Tong X, Kang L, Pei S, Ouyang Y, Jiang L, Ding Y, Zhao X, Li S, Yang Y, Huang J, Zeng Q. Fu C, et al. Among authors: li s. Mol Med Rep. 2020 Mar;21(3):1421-1430. doi: 10.3892/mmr.2020.10950. Epub 2020 Jan 17. Mol Med Rep. 2020. PMID: 32016458 Free PMC article. Review.
Enantiomer-dependent immunological response to chiral nanoparticles.
Xu L, Wang X, Wang W, Sun M, Choi WJ, Kim JY, Hao C, Li S, Qu A, Lu M, Wu X, Colombari FM, Gomes WR, Blanco AL, de Moura AF, Guo X, Kuang H, Kotov NA, Xu C. Xu L, et al. Among authors: li s. Nature. 2022 Jan;601(7893):366-373. doi: 10.1038/s41586-021-04243-2. Epub 2022 Jan 19. Nature. 2022. PMID: 35046606
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Xia Y, et al. Among authors: li s. J Immunother Cancer. 2022 Apr;10(4):e004656. doi: 10.1136/jitc-2022-004656. J Immunother Cancer. 2022. PMID: 35379737 Free PMC article. Clinical Trial.
Layer-engineered interlayer excitons.
Tan Q, Rasmita A, Li S, Liu S, Huang Z, Xiong Q, Yang SA, Novoselov KS, Gao WB. Tan Q, et al. Among authors: li s. Sci Adv. 2021 Jul 23;7(30):eabh0863. doi: 10.1126/sciadv.abh0863. Print 2021 Jul. Sci Adv. 2021. PMID: 34301603 Free PMC article.
579 results